Stay updated on Pembrolizumab & Lanreotide for GI NETs Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The site footer now identifies the ClinicalTrials.gov version as v3.8.1 instead of v3.8.0.
    Difference
    0.1%
    Check dated 2026-11-22T13:30:41.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    A sitewide NIH notice about terminology changes during a federal transition no longer appears at the top of the page.
    Difference
    1%
    Check dated 2026-11-08T13:16:21.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0, while the study record remains unavailable and displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T13:53:58.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    A sitewide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T13:31:10.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov study page still displays a 403 Forbidden error. Its footer revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T13:51:21.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T14:58:06.000Z thumbnail image

Stay in the know with updates to Pembrolizumab & Lanreotide for GI NETs Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lanreotide for GI NETs Clinical Trial page.